There are few reports about the effect of glucocorticoids in the treatment of acute pancreatitis in humans. This study aims to evaluate the effect of glucocorticoids in the treatment of acute pancreatitis by propensity score matching analysis. Acute pancreatitis patients admitted between 2014 and 2019 were collected from the database and analyzed. Included patients were divided into the glucocorticoids-used group (GC group) and the non-glucocorticoids-used group (NGC group) according to whether glucocorticoids were used. A total of 818 eligible patients were included in the final analysis. Seventy-six patients were treated with glucocorticoids, and 742 patients were treated without glucocorticoids. Before propensity score matching, the triglyceride levels (38.2 ± 18.5 vs. 20.2 ± 16.8, P < 0.05) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (7.1 ± 2.5 vs. 4.5 ± 2.1, P < 0.05) at admission were significantly higher in the GC group than in the NGC group. The incidence of multi-organ failure (33.3% vs. 11.9%, P < 0.05) was significantly higher in the GC group than in the NGC group. Patients in the GC group showed a positive balance of fluid intake and output over 72 h. After 1:1 propensity score matching, 59 patients from each group (GC and NGC) were included in the analysis. There were no significant differences in age, sex, body mass index, triglycerides, or APACHE II scores between the two groups (P > 0.05), and the patients’ clinical outcomes were reversed. The proportion of patients with organ failure (40.7% vs. 52.5%, p < 0.05) and multi-organ failure (35.0% vs. 67.7%, P < 0.05) was significantly lower in the GC group than in the NGC group. Furthermore, patients in the GC group had significantly shorter lengths of hospital stay (12.9 ± 5.5 vs. 16.3 ± 7.7, P < 0.05) and costs (25,348.4 ± 2512.6vs. 32,421.7 ± 2813.3, P < 0.05) than those in the NGC group. This study presents preliminary confirmation of the beneficial effect of glucocorticoids in the treatment of acute pancreatitis. More high-quality prospective studies are needed in the future.

中文翻译：

---

急性胰腺炎中的糖皮质激素：倾向评分匹配分析

很少有关于糖皮质激素治疗人类急性胰腺炎作用的报道。本研究旨在通过倾向评分匹配分析评估糖皮质激素治疗急性胰腺炎的效果。从数据库中收集并分析了 2014 年至 2019 年间收治的急性胰腺炎患者。根据是否使用糖皮质激素将纳入患者分为糖皮质激素使用组（GC组）和非糖皮质激素使用组（NGC组）。共有 818 名符合条件的患者被纳入最终分析。76 名患者接受了糖皮质激素治疗，742 名患者未接受糖皮质激素治疗。在倾向得分匹配之前，甘油三酯水平（38.2 ± 18.5 vs. 20.2 ± 16.8，P < 0。05) 和急性生理学和慢性健康评估 II (APACHE II) 评分 (7.1 ± 2.5 vs. 4.5 ± 2.1, P < 0.05) 在入院时，GC 组显着高于 NGC 组。GC 组多器官衰竭的发生率（33.3% vs. 11.9%，P < 0.05）显着高于 NGC 组。GC 组的患者在 72 小时内表现出液体摄入和输出的正平衡。在 1:1 倾向评分匹配后，每组（GC 和 NGC）的 59 名患者被纳入分析。两组患者的年龄、性别、体重指数、甘油三酯或APACHE II评分均无显着差异（P>0.05），患者的临床结局发生逆转。器官衰竭（40.7% vs. 52.5%，p < 0.05）和多器官衰竭（35.0% vs. 67.7%，P < 0）患者的比例。05) GC 组显着低于 NGC 组。此外，与 NGC 组相比，GC 组患者的住院时间（12.9 ± 5.5 对 16.3 ± 7.7，P < 0.05）和费用（25,348.4 ± 2512.6 对 32,421.7 ± 2813.3，P < 0.05）显着缩短. 本研究初步证实了糖皮质激素治疗急性胰腺炎的有益作用。未来需要更多高质量的前瞻性研究。本研究初步证实了糖皮质激素治疗急性胰腺炎的有益作用。未来需要更多高质量的前瞻性研究。本研究初步证实了糖皮质激素治疗急性胰腺炎的有益作用。未来需要更多高质量的前瞻性研究。